Evaluation of factors associated with recruitment in hematological clinical trials: A retrospective cohort study

Hematology

Volumn 15, Issue 6, 2010, Pages 373-377

  Lemieux, Julie ^a,b   Amireault, Carl ^a   Camden, Stephanie ^b   Poulin, Jacqueline ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

clinical trials; enrolment; Recruitment

Indexed keywords

ARTICLE; CANCER RESEARCH; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; HEMATOLOGIC MALIGNANCY; PATIENT IDENTIFICATION; PATIENT PARTICIPATION; PATIENT SELECTION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; REFUSAL TO PARTICIPATE; RESEARCH ETHICS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78649372296     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12719010991623     Document Type: Article

References (13)

1. Tournoux C, Katsahian S, Chevret S, Levy V. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer 2006; 106: 258-270.
2. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720-2726.
3. Lemieux J, Goodwin PJ, Pritchard KI et al. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. J Clin Oncol 2008; 26: 4458-4465.
4. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004; 363: 263-270.
5. Hebert-Croteau N, Brisson J, Lemaire J, Latreille J. The benefit of participating to clinical research. Breast Cancer Res Treat 2005; 91: 279-281.
6. Canadian Cancer Society's Steering Committee. Canadian cancer statistics 2009. Toronto, Ont.: Canadian Cancer Society, 2009.
7. Meropol NJ, Buzaglo JS, Millard J et al. Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw 2007; 5: 655-664.
8. Hunter CP, Frelick RW, Feldman AR et al. Selection factors in clinical trials: results from the community clinical oncology program physician's patient log. Cancer Treat Rep 1987; 71: 559-565.
9. Hjorth M, Holmberg E, Rodjer S, Taube A, Westin J. Physicians' attitudes toward clinical trials and their relationship to patient accrual in a Nordic multicenter study on myeloma. Control Clin Trials 1996; 17: 372-386.
10. Mengis C, Aebi S, Tobler A, Dahler W, Fey MF. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003; 21: 3933-3939.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
12. Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med 2002; 137: 10-16.
13. Fuks A, Weijer C, Freedman B, Shapiro S, Skrutkowska M, Riaz A. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol 1998; 51: 69-79.